Vaginitis medical therapy: Difference between revisions
Line 118: | Line 118: | ||
*Because of the high rate of reinfection among patients in whom trichomoniasis was diagnosed (17% were reinfected within 3 months in one study), rescreening for [[T. vaginalis]] at 3 months following initial infection can be considered for sexually active women with trichomoniasis. | *Because of the high rate of reinfection among patients in whom trichomoniasis was diagnosed (17% were reinfected within 3 months in one study), rescreening for [[T. vaginalis]] at 3 months following initial infection can be considered for sexually active women with trichomoniasis. | ||
*No data support rescreening in men diagnosed with T. vaginalis. | |||
*While most recurrent T. vaginalis infections are thought to result from having sex with an untreated partner (i.e., reinfection), some recurrent cases can be attributed to diminished susceptibility to metronidazole. | *While most recurrent T. vaginalis infections are thought to result from having sex with an untreated partner (i.e., reinfection), some recurrent cases can be attributed to diminished susceptibility to metronidazole. | ||
Revision as of 04:41, 6 February 2014
Please help WikiDoc by adding more content here. It's easy! Click here to learn about editing.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
The cause of the infection determines the appropriate treatment. It may include oral or topical antibiotics and/or antifungal creams, antibacterial creams, or similar medications. A cream containing cortisone may also be used to relieve some of the irritation. If an allergic reaction is involved, an antihistamine may also be prescribed. For women who have irritation and inflammation caused by low levels of estrogen (postmenopausal), a topical estrogen cream might be prescribed.
Bacterial Vaginosis
- Treatment is recommended for women with symptoms.
- The established benefits of therapy in nonpregnant women are to relieve vaginal symptoms and signs of infection. Other potential benefits to treatment include reduction in the risk for acquiring C. trachomatis or N. gonorrhoeae, HIV, and other viral STDs.
- Providers should consider patient preference, possible side-effects, drug interactions, and other coinfections when selecting a regimen.
- Women should be advised to refrain from intercourse or to use condoms consistently and correctly during the treatment regimen.
- Douching might increase the risk for relapse, and no data support the use of douching for treatment or relief of symptoms.
|
Follow-Up
Follow-up visits are unnecessary if symptoms resolve. Because recurrence of BV is common, women should be advised to
- return for evaluation if symptoms recur.* Detection of certain BV-associated organisms have been associated with antimicrobial resistance and might determine risk for subsequent treatment failure .
- Using a different treatment regimen might be an option in patients who have a recurrence; however, re-treatment with the same topical regimen is another acceptable approach for treating recurrent BV during the early stages of infection .
- Monthly oral metronidazole administered with fluconazole has also been evaluated as suppressive therapy.
Management of Sex Partners
The results of clinical trials indicate that a woman’s response to therapy and the likelihood of relapse or recurrence are not affected by treatment of her sex partner(s). Therefore, routine treatment of sex partners is not recommended.
Special Considerations
Allergy or Intolerance to the Recommended Therapy
Intravaginal clindamycin cream is preferred in case of allergy or intolerance to metronidazole or tinidazole. Intravaginal metronidazole gel can be considered for women who do not tolerate systemic metronidazole. Intravaginal metronidazole should not be administered to women allergic to metronidazole.
Pregnancy
- Treatment is recommended for all pregnant women with symptoms.
- Although BV is associated with adverse pregnancy outcomes, including premature rupture of membranes, preterm labor, preterm birth, intra-amniotic infection, and postpartum endometritis, the only established benefit of therapy for BV in pregnant women is the reduction of symptoms and signs of vaginal infection.
- Additional potential benefits include reducing the risk for infectious complications associated with BV during pregnancy and reducing the risk for other infections (other STDs or HIV).
Trichomoniasis
|
- Topically applied antimicrobials (e.g., metronidazole gel) are unlikely to achieve therapeutic levels in the urethra or perivaginal glands; therefore, use of this gel is not recommended.
- Several other topically applied antimicrobials occasionally have been used for treatment of trichomoniasis; however, these preparations likely are no more effective than metronidazole gel.
Follow-Up
- Because of the high rate of reinfection among patients in whom trichomoniasis was diagnosed (17% were reinfected within 3 months in one study), rescreening for T. vaginalis at 3 months following initial infection can be considered for sexually active women with trichomoniasis.
- No data support rescreening in men diagnosed with T. vaginalis.
- While most recurrent T. vaginalis infections are thought to result from having sex with an untreated partner (i.e., reinfection), some recurrent cases can be attributed to diminished susceptibility to metronidazole.
Management of Sex Partners
- Sex partners of patients with T. vaginalis should be treated. Patients should be instructed to abstain from sex until they and their sex partners are cured (i.e., when therapy has been completed and patient and partner[s] are asymptomatic).
- Male partners should be evaluated and treated with either tinidazole in a single dose of 2 g orally or metronidazole twice a day at 500 mg orally for 7 days.
Candida
|